Andrew Galler
Stock Analyst at Morgan Stanley
(0.51)
# 3,867
Out of 4,732 analysts
28
Total ratings
27.78%
Success rate
-15.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Galler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMCR Immunocore Holdings | Downgrades: Equal-Weight | $74 → $35 | $29.02 | +20.61% | 12 | Dec 13, 2024 | |
| FOLD Amicus Therapeutics | Maintains: Equal-Weight | $14 → $15 | $9.41 | +59.40% | 5 | Nov 9, 2023 | |
| SLN Silence Therapeutics | Initiates: Equal-Weight | $18 | $5.12 | +251.56% | 1 | Dec 9, 2022 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Equal-Weight | $41 → $37 | $19.56 | +89.16% | 2 | Nov 29, 2022 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $57 → $56 | $31.43 | +78.17% | 2 | Nov 10, 2022 | |
| VIR Vir Biotechnology | Maintains: Underweight | $15 → $18 | $10.11 | +78.04% | 2 | Nov 4, 2022 | |
| PTCT PTC Therapeutics | Initiates: Equal-Weight | $54 | $43.84 | +23.18% | 1 | Sep 9, 2022 | |
| HALO Halozyme Therapeutics | Initiates: Overweight | $50 | $54.80 | -8.76% | 1 | Sep 9, 2022 | |
| ADCT ADC Therapeutics | Initiates: Outperform | $44 | $1.83 | +2,304.37% | 1 | Nov 9, 2021 | |
| MRNA Moderna | Initiates: Outperform | $304 | $34.06 | +792.54% | 1 | Nov 9, 2021 |
Immunocore Holdings
Dec 13, 2024
Downgrades: Equal-Weight
Price Target: $74 → $35
Current: $29.02
Upside: +20.61%
Amicus Therapeutics
Nov 9, 2023
Maintains: Equal-Weight
Price Target: $14 → $15
Current: $9.41
Upside: +59.40%
Silence Therapeutics
Dec 9, 2022
Initiates: Equal-Weight
Price Target: $18
Current: $5.12
Upside: +251.56%
Arrowhead Pharmaceuticals
Nov 29, 2022
Maintains: Equal-Weight
Price Target: $41 → $37
Current: $19.56
Upside: +89.16%
Ionis Pharmaceuticals
Nov 10, 2022
Maintains: Overweight
Price Target: $57 → $56
Current: $31.43
Upside: +78.17%
Vir Biotechnology
Nov 4, 2022
Maintains: Underweight
Price Target: $15 → $18
Current: $10.11
Upside: +78.04%
PTC Therapeutics
Sep 9, 2022
Initiates: Equal-Weight
Price Target: $54
Current: $43.84
Upside: +23.18%
Halozyme Therapeutics
Sep 9, 2022
Initiates: Overweight
Price Target: $50
Current: $54.80
Upside: -8.76%
ADC Therapeutics
Nov 9, 2021
Initiates: Outperform
Price Target: $44
Current: $1.83
Upside: +2,304.37%
Moderna
Nov 9, 2021
Initiates: Outperform
Price Target: $304
Current: $34.06
Upside: +792.54%